Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
| Revenue (TTM) | $25.11B |
| Gross Profit (TTM) | $14.75B |
| EBITDA | $8.03B |
| Operating Margin | 19.80% |
| Return on Equity | 7.61% |
| Return on Assets | 3.95% |
| Revenue/Share (TTM) | $35.47 |
| Book Value | $74.81 |
| Price-to-Book | 2.96 |
| Price-to-Sales (TTM) | 6.41 |
| EV/Revenue | 7.09 |
| EV/EBITDA | 23.46 |
| Quarterly Earnings Growth (YoY) | 59.70% |
| Quarterly Revenue Growth (YoY) | 5.50% |
| Shares Outstanding | $702.99M |
| Float | $625.85M |
| % Insiders | 10.82% |
| % Institutions | 84.25% |
Volatility is currently contracting
DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.
Evaluate the expected performance of Danaher (DHR) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and data WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher's broader effort to shape the future of AI-enabled science, the companies are working to combine Danaher's scientific instrumentation, automation technologies, laboratory workflow software and domain expertise with NVIDIA accelerated computing and AI technologies.
WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D.
Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DHR and any ticker you trade — then tracks every position and per-strategy win rate.
